GRI Bio, Inc. 8-K

What Happened

• On February 4, 2026, GRI Bio, Inc. announced and furnished a press release reiterating its financial results for the fiscal year 2025 and summarizing recent company highlights. The press release is included as Exhibit 99.1 to the Form 8-K. The report was signed by Chief Financial Officer Leanne Kelly.

Key Details

• Date of filing and press release: February 4, 2026.
• Event: Company reiterated its fiscal 2025 financial results and provided recent operational/strategic highlights.
• Press release furnished as Exhibit 99.1 (and an Inline XBRL cover page as Exhibit 104).
• The information is furnished (not “filed”) and therefore not subject to Section 18 liability and is not incorporated by reference into other SEC filings.

Why It Matters

• Investors should review the furnished press release to see the company’s reported FY2025 earnings, revenue and any operational highlights or guidance it summarized. Because the company reaffirmed its FY2025 results, this filing does not indicate a change to previously released financials; it simply restates those results and provides highlights. Note the legal caveat that the disclosure is furnished—not filed—so it has different liability and incorporation implications than a filed disclosure.